Medicare’s 2026 drug price negotiations under the Inflation Reduction Act aim to lower the cost of expensive medications, ...

Pfizer's coronavirus vaccine could face some headwinds in the near future. The company will enter a period of patent cliffs ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer commented on along with the recent macro rally.

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

The hospital lobby has filed a lawsuit seeking to block the federal government’s 340B Rebate Model Pilot Program, which is ...

The new rule is expected to extend the telemedicine flexibilities through the end of 2026 and will maintain the status quo while the DEA and the Department of Health and Human Services work toward a ...

Data from the "ADEPT-2" study, which analysts had hoped would arrive before year's end, are now expected sometime in 2026.

Yet the stock (BMY) was up about 6% on Wednesday after the drug giant announced the delay. In its statement, the company said it now expects to share the data from the Phase 3 trial sometime next year ...

Medicare Part B costs will rise in 2026. Here's what to expect, including higher prescription drug prices and payment changes that will affect your wallet.

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Dr Mark Porter, a GP who has appeared on The One Show said 'about one in ten of those affected never return home' ...

Pfizer's strategy that will help it rebound from recent struggles is in full motion. It says a lot that the company continues ...